Novo Nordisk A/S (NVO) shares fell 7.65% to 260.00 as pressure mounted around the company's growth targets, intensifying competition, and its future medicine development plans. Management faces calls for a clearer strategy beyond semaglutide, the active ingredient behind its flagship products, as major patent expirations approach early in the next decade. Novo still leads the obesity market, but recent pipeline setbacks have weakened confidence in its longer-term growth trajectory and earnings outlook. The size of the single-session decline underscores how sensitive the stock has become to questions about what sustains revenue once semaglutide matures.

Novo Faces Pressure to Expand Beyond Semaglutide

Novo built much of its recent success on Wegovy and Ozempic, both of which use the active ingredient semaglutide. Wegovy's 2021 launch helped lift Novo into Europe's most valuable listed company during 2023, when its market capitalization exceeded $600 billion. The share price has since dropped more than 70% from its peak as competition and development risks have increased — a reversal that illustrates how heavily the market had priced in the obesity opportunity at its height.

Data from LSEG projects that Lilly's Zepbound will outsell Wegovy by more than $7 billion in 2026. That projected gap highlights growing competitive pressure across the global obesity market and raises questions about Novo's future market share. Separately, semaglutide patent protection begins expiring in the early 2030s, creating another significant challenge for long-term revenue growth. Patent expiries carry particular weight in the pharmaceutical industry because they open the door to lower-priced competing versions, a shift that has historically compressed branded sales.

Novo now needs additional growth engines outside its established diabetes and obesity businesses to reduce concentration risk over time. Cardiovascular treatments and rare diseases could provide new revenue opportunities if management expands through acquisitions or licensing agreements. Such moves would also give Novo more options as its current flagship products move steadily closer to patent expiry, and dealmaking has become the standard route large drugmakers use to refill pipelines ahead of a patent cliff.

Pipeline Setbacks Increase Strategy Pressure

CEO Mike Doustdar, who took the top job more than one year ago, has tightened and removed weak development programs. He has also pursued targeted partnerships and acquisitions as Novo works to rebuild its increasingly thin late-stage development pipeline. Even so, recent clinical setbacks have increased pressure on management to show stronger progress across several upcoming development programs. Late-stage programs draw the most scrutiny because they sit closest to regulatory review and potential market entry, leaving the least time to recover from a failure.

Novo recently stopped trials for the experimental heart drug ziltivekimab, adding another setback outside its core obesity and diabetes portfolio. The company also faced disappointment from CagriSema, which had carried expectations as a potential successor to Wegovy. Those results deepened concerns about whether internal research can deliver enough products before semaglutide exclusivity weakens next decade.

Management raised its 2026 sales and operating profit guidance in August after previously issuing a significantly weaker outlook. The updated range now points to growth between zero and minus 6% at constant exchange rates versus 2025 — a striking range for a company that was Europe's most valuable listed company as recently as 2023. Even so, that improvement does not remove questions surrounding medium-term targets, product diversification, and future earnings durability.

Wegovy Pill Supports Near-Term Position

Novo still holds an important near-term advantage through the Wegovy pill, which reached the market before Lilly's competing oral treatment. The oral medicine broadens access for patients who prefer pills instead of injectable weight-loss treatments across major markets, and arriving first gives Novo an early window with prescribers and patients before rivals catch up. However, the pill still relies on semaglutide and therefore does not solve the company's approaching patent challenge.

The company also faces rising competition from drugmakers developing obesity treatments with different mechanisms, formats, and dosing options. AstraZeneca and other rivals are building pipelines that could increase pressure on established medicines later this decade, and a more crowded field typically tightens pricing and prescribing share across a treatment category. Novo's future growth will therefore depend on stronger differentiation and a broader pipeline across several therapeutic areas.

Novo may also shift more development attention toward zenagamtide after weaker results reduced enthusiasm around CagriSema among market analysts. A stronger external deal strategy could complement internal development and add late-stage assets before major patent expirations arrive. For now, Novo's market position remains substantial, but how the coming quarters unfold — clearer medium-term targets, further deal announcements, and progress on zenagamtide — will help determine how much of that position carries into the next decade.

This article first appeared on Blockonomi: Novo Nordisk A/S (NVO) Stock: Wegovy Lead Meets Long-Term Challenges